Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism
Abstract
SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis - osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-α) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-α blockade therapy. © Clinical Rheumatology 2007.
Más información
| Título según WOS: | Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism |
| Título según SCOPUS: | Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism |
| Título de la Revista: | CLINICAL RHEUMATOLOGY |
| Volumen: | 27 |
| Número: | 4 |
| Editorial: | SPRINGER LONDON LTD |
| Fecha de publicación: | 2008 |
| Página de inicio: | 533 |
| Página final: | 535 |
| Idioma: | English |
| URL: | http://link.springer.com/10.1007/s10067-007-0767-y |
| DOI: |
10.1007/s10067-007-0767-y |
| Notas: | ISI, SCOPUS |